Molecular biology reports · 2026
Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeytunlu Mustafa Barış, Duzdag Fazilet Esra Incedere, Esin Hüseyin, Aktan Cagdas, Kaymaz Burcin Tezcanli
Аннотация
BACKGROUND: Circulating miRNAs (c-miRNAs) are promising non-invasive biomarkers for breast cancer detection, but reproducible signatures remain limited. This study aimed to identify a circulating miRNA signature for invasive ductal breast carcinoma, evaluate its discriminatory performance in an independent serum cohort, and explore the biological context of the selected c-miRNAs.
METHODS AND RESULTS: Serum expression of 21 candidate c-miRNAs was analyzed by RT-qPCR in 46 treatment-naive invasive ductal breast carcinoma patients and 46 healthy controls. Whole-blood expression of immune checkpoint-related genes (PDCD1, CD274, CTLA4, and LAG3) was also assessed in 50 patients and 46 controls. Among the 21 candidates, 12 c-miRNAs were significantly dysregulated after FDR correction. miR-6838-5p and miR-195-5p showed the strongest discriminatory performance and were combined into a two-miRNA logistic regression model. This model achieved an AUC of 0.923 (95% CI: 0.873-0.974) in the discovery cohort and an optimism-corrected AUC of 0.917 after 1,000 bootstrap iterations. In the independent GSE73002 serum cohort, including 1,280 breast cancer patients and 2,684 non-cancer controls, the same two-miRNA combination retained strong ROC-derived discriminatory performance with an AUC of 0.939 (95% CI: 0.930-0.948). Exploratory downstream analyses provided additional biological context.
CONCLUSIONS: The miR-6838-5p/miR-195-5p combination represents a promising circulating miRNA signature for invasive ductal breast carcinoma. Its consistent discriminatory performance in the discovery cohort and an independent serum cohort supports further evaluation in larger prospective studies. Additional work in clinically diverse cohorts, including benign breast disease and early-stage populations, as well as paired serum-tissue and functional validation studies, is needed to define its clinical applicability and biological origin.
METHODS AND RESULTS: Serum expression of 21 candidate c-miRNAs was analyzed by RT-qPCR in 46 treatment-naive invasive ductal breast carcinoma patients and 46 healthy controls. Whole-blood expression of immune checkpoint-related genes (PDCD1, CD274, CTLA4, and LAG3) was also assessed in 50 patients and 46 controls. Among the 21 candidates, 12 c-miRNAs were significantly dysregulated after FDR correction. miR-6838-5p and miR-195-5p showed the strongest discriminatory performance and were combined into a two-miRNA logistic regression model. This model achieved an AUC of 0.923 (95% CI: 0.873-0.974) in the discovery cohort and an optimism-corrected AUC of 0.917 after 1,000 bootstrap iterations. In the independent GSE73002 serum cohort, including 1,280 breast cancer patients and 2,684 non-cancer controls, the same two-miRNA combination retained strong ROC-derived discriminatory performance with an AUC of 0.939 (95% CI: 0.930-0.948). Exploratory downstream analyses provided additional biological context.
CONCLUSIONS: The miR-6838-5p/miR-195-5p combination represents a promising circulating miRNA signature for invasive ductal breast carcinoma. Its consistent discriminatory performance in the discovery cohort and an independent serum cohort supports further evaluation in larger prospective studies. Additional work in clinically diverse cohorts, including benign breast disease and early-stage populations, as well as paired serum-tissue and functional validation studies, is needed to define its clinical applicability and biological origin.